Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Key Takeaways Biogen's MS drugs and Spinraza face mounting competition, pressuring overall sales growth.New launches like Leqembi, Skyclarys, and Zurzuvae delivered strong sequential gains.Despite rising new-drug sales, BIIB's total 2025 revenue is projected to remain flat versus 2024 levels.Sales of Biogen’s (BIIB) key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is hurting top-line growth ...